Stent

Insights on the Vascular Stents Global Market to 2026 - by Product Type, Material, Mode of Delivery, End-user and Region - ResearchAndMarkets.com

Friday, June 11, 2021 - 12:40pm

The global vascular stents market reached a value of US$ 9.4 Billion in 2020.

Key Points: 
  • The global vascular stents market reached a value of US$ 9.4 Billion in 2020.
  • Vascular stents are usually made of polyethylene, polypropylene or non-absorbable materials such as stainless steel or cobalt-chromium alloys.
  • Looking forward, the publisher expects the global vascular stents market to grow at a CAGR of 6.1% during 2021-2026.
  • Key Questions Answered in This Report:
    How has the global vascular stents market performed so far and how will it perform in the coming years?

Global Neurovascular Devices/Interventional Neurology Market (2021 to 2026) - Rise in Demand for Minimally Invasive Neurosurgical Procedures Presents Opportunities - ResearchAndMarkets.com

Tuesday, June 8, 2021 - 12:34pm

The neurovascular devices/ interventional neurology market size is expected to grow from an estimated USD 2.5 billion in 2021 to USD 3.8 billion by 2026, at a CAGR of 8.6%.

Key Points: 
  • The neurovascular devices/ interventional neurology market size is expected to grow from an estimated USD 2.5 billion in 2021 to USD 3.8 billion by 2026, at a CAGR of 8.6%.
  • On the basis of product, the neurovascular devices/interventional neurology market is segmented into aneurysm coiling & embolization devices, cerebral balloon angioplasty & stenting systems, support devices, and neuro thrombectomy devices.
  • Based on end-user, the neurovascular devices/interventional neurology market has been segmented into hospitals & surgical centers, ambulatory care centers, and research laboratories, and academic institutes.
  • North America accounted for the largest market share in the neurovascular devices/interventional neurology market in 2020.

Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters

Tuesday, June 1, 2021 - 12:00pm

JADE is an OTW balloon catheter for PTA in the peripheral vasculature, including obstructed native arteries and synthetic arteriovenous dialysis fistulae, as well as for post-dilatation of balloon expandable and self-expanding stents.

Key Points: 
  • JADE is an OTW balloon catheter for PTA in the peripheral vasculature, including obstructed native arteries and synthetic arteriovenous dialysis fistulae, as well as for post-dilatation of balloon expandable and self-expanding stents.
  • JADE is a non-compliant balloon designed for high pressure tolerance and balloon dilatation with even pressure distribution for the treatment of complex lesions.
  • The predictable, uniform inflation of these non-compliant balloons allows for accuracy in balloon sizing and reduces the potential for vessel recoil.
  • Said Dr. Rao, The deliverability of the JADE balloons, whether it be on the 0.014, 0.018 or 0.035 platform, is exceptional.

Worldwide Drug-Eluting Stents Industry to 2027 - Surge in Demand for Minimally Invasive Surgical Procedures is Driving Growth - ResearchAndMarkets.com

Tuesday, May 25, 2021 - 1:37pm

Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.

Key Points: 
  • Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.
  • Polymer-based drug-eluting coating stents are designed to allow consistent and controlled release of drug from stent surface into arteries.
  • Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.
  • Profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook of the global market.

amg International GmbH, a Q3 Medical Devices Ltd Company, Receives European CE Mark Approval for UNITY-B™ Biodegradable Stent

Monday, May 24, 2021 - 10:38pm

The Company announced that it has received CE Mark approval for its second fully biodegradable product, the UNITY-B balloon expandable biodegradable biliary stent (BEBS) for endoscopic use.

Key Points: 
  • The Company announced that it has received CE Mark approval for its second fully biodegradable product, the UNITY-B balloon expandable biodegradable biliary stent (BEBS) for endoscopic use.
  • The UNITY-B Biodegradable implant was developed as a complimentary biodegradable metallic stent to amg's ARCHIMEDES biodegradable pancreaticobiliary stent, which is currently available in fast, medium, and long-lasting degradation profiles.
  • ARCHIMEDES obtained CE mark approval in 2018 and was subsequently launched through a global distribution partnership with Medtronic.
  • "The CE mark approval of the UNITY-B stent represents yet another milestone for amg International and all the companies of Q3 Medical and our mission to 'Create Value By Helping People'.

Confluent Medical Technologies Expanding, Adding Capacity for Nitinol Processing and Catheter Manufacturing

Monday, May 24, 2021 - 4:59pm

Confluent Medical Technologies (Confluent), today announced a significant expansion of their Costa Rica manufacturing by adding a new facility to accommodate the increase in customer demand for specialized medical devices utilizing Nitinol components and complex catheters.

Key Points: 
  • Confluent Medical Technologies (Confluent), today announced a significant expansion of their Costa Rica manufacturing by adding a new facility to accommodate the increase in customer demand for specialized medical devices utilizing Nitinol components and complex catheters.
  • The new site will greatly expand Confluents capacity to process Nitinol components, as well as produce complex catheters using a combination of clean rooms and white-space manufacturing.
  • Confluent has been experiencing consistent and strong growth in recent years, says Confluent President & CEO, Dean Schauer.
  • Confluent supports some of the fastest growing medical device markets such as interventional Neurovascular, Electrophysiology, Structural Heart and Peripheral Vascular.

Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina

Tuesday, May 11, 2021 - 1:00pm

b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.

Key Points: 
  • b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.
  • View the full release here: https://www.businesswire.com/news/home/20210511005366/en/\nFeaturing a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation in polymer-based therapies for AAA patients.
  • ALTO utilizes a low-profile delivery system and, unlike standard EVAR devices, features an exclusive conformable sealing ring that molds in-situ to the patient\xe2\x80\x99s specific aortic neck anatomy.
  • The company\xe2\x80\x99s current commercial EVAR products include the AFX\xc2\xae2 device and the ALTO\xc2\xae Abdominal Stent Graft System.

InspireMD Announces First Quarter 2021 Financial Results

Tuesday, May 11, 2021 - 11:00am

We believe listing on Nasdaq will help broaden our stockholder base, increase interest by institutional and fundamental investors, and create stockholder value.

Key Points: 
  • We believe listing on Nasdaq will help broaden our stockholder base, increase interest by institutional and fundamental investors, and create stockholder value.
  • Stroke is the leading cause of death in China, and the country is believed to be the second largest market for peripheral stent procedures.
  • Investors and security holders are urged to read these documents free of charge on the SEC\xe2\x80\x99s web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

Cardiovascular Systems, Inc. Reports Fiscal 2021 Third-Quarter Financial Results

Thursday, May 6, 2021 - 9:05pm

Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation.

Key Points: 
  • Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation.
  • These systems use a diamond-coated crown, attached to an orbiting shaft, which sands away plaque while preserving healthy vessel tissue \xe2\x80\x94 a critical factor in preventing reoccurrences.
  • Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions.
  • CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart.

Worldwide Neurovascular Devices Industry to 2029 - Featuring Penumbra, Phenox and Stryker Among Others - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:04pm

Availability of a wide range of neurovascular devices, mainly in the aneurysm coiling and embolization devices segment enable professionals to meet the active demand.

Key Points: 
  • Availability of a wide range of neurovascular devices, mainly in the aneurysm coiling and embolization devices segment enable professionals to meet the active demand.
  • As per the Internet Stroke Center statistics, around 75% of strokes take place in the age group of 60-65.
  • For example, with the introduction of new flow diversion stent technique, the need to treat complex aneurysms with bypasses has fallen down.
  • However, lack of skilled neurologists in hospitals is limiting the growth of neurovascular devices market.\n'